1. Home
  2. Author
  3. Arasaki O

Arasaki O

References (2)

Title : Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy - Furuhashi_2020_Cardiovasc.Diabetol_19_89
Author(s) : Furuhashi M , Sakuma I , Morimoto T , Higashiura Y , Sakai A , Matsumoto M , Sakuma M , Shimabukuro M , Nomiyama T , Arasaki O , Node K , Ueda S
Ref : Cardiovasc Diabetol , 19 :89 , 2020
Abstract :
PubMedSearch : Furuhashi_2020_Cardiovasc.Diabetol_19_89
PubMedID: 32539832

Title : Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial - Ueda_2018_Cardiovasc.Drugs.Ther_32_73
Author(s) : Ueda S , Shimabukuro M , Arasaki O , Node K , Nomiyama T , Morimoto T
Ref : Cardiovasc Drugs Ther , 32 :73 , 2018
Abstract :
PubMedSearch : Ueda_2018_Cardiovasc.Drugs.Ther_32_73
PubMedID: 29435776